Bertrand Routy

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Journal: Gut microbes

Published: July 15, 2026

A "healthy gut state" as the key determinant of immune checkpoint inhibitor efficacy.

A "healthy gut state" as the key determinant of immune checkpoint inhibitor efficacy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 13, 2026

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: March 13, 2026

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Journal: Cancers

Published: January 04, 2026

Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence.

Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence.

Journal: Nature cancer

Published: December 10, 2025

Toward Personalized Neoadjuvant Strategies: Using Metabolic and Biological Response to Guide Treatment Deescalation or Intensification.

Toward Personalized Neoadjuvant Strategies: Using Metabolic and Biological Response to Guide Treatment Deescalation or Intensification.

Journal: The Annals of thoracic surgery

Published: December 08, 2025

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Journal: The Lancet. Oncology

Published: December 06, 2025

The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects.

The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects.

Journal: The British journal of dermatology

Published: November 06, 2025

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Journal: The British journal of dermatology

Published: November 06, 2025

Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma.

Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma.

Journal: Current oncology (Toronto, Ont.)

Published: October 01, 2025

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Journal: Microbiome

Published: September 02, 2025

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.

Journal: Cancer cell

Published: September 01, 2025

Showing 1-12 of 149

Last Updated: 09/26/2026